Related Experiment Videos
Inhibitory receptors, ITIM sequences and phosphatases
1Department of Biochemistry, Mount Sinai School of Medicine, 1 Gustave Levy Place, New York City, NY 10029, USA. junkele@smtplink.mssm.edu
Current Opinion in Immunology
|June 1, 1997
Summary
Inhibitory receptors utilize an immunoreceptor tyrosine-based inhibition motif (ITIM) to recruit phosphatases like SHP-1, SHIP, and SHP-2. These enzymes are crucial for inhibiting signaling pathways in various immune cells.
Area of Science:
- Immunology
- Molecular Biology
- Cell Signaling
Background:
- Inhibitory receptors, including FcgammaRII, killer cell inhibitory receptors, and B22, share a common immunoreceptor tyrosine-based inhibition motif (ITIM).
- Phosphorylated ITIMs serve as docking sites for Src homology 2 (SH2) domain-containing enzymes.
- Key enzymes recruited include protein tyrosine phosphatase SHP-1, inositol 5-phosphatase SHIP, and tyrosine phosphatase SHP-2.
Purpose of the Study:
- To elucidate the role of ITIM-mediated recruitment of SHP-1, SHIP, and SHP-2 in regulating immune cell signaling.
- To understand how these phosphatases inhibit signaling cascades initiated by receptor ligation.
Main Methods:
- Analysis of tyrosine phosphorylation within ITIMs.
- Investigation of SH2 domain interactions with phosphorylated ITIMs.
- Studies on the recruitment of SHP-1, SHIP, and SHP-2 to inhibitory receptors.
- Examination of signaling inhibition downstream of BCR, TCR, FcgammaRIII, and FcepsilonRI ligation.
Main Results:
- ITIM phosphorylation creates docking sites for SHP-1, SHIP, and SHP-2.
- Cytotoxic T-lymphocyte antigen-4 utilizes a similar motif to recruit SHP-2.
- These enzymes collectively inhibit signaling cascades triggered by various immune receptor activations.
Conclusions:
- SHP-1, SHIP, and SHP-2 are critical negative regulators of immune receptor signaling.
- The specific contribution of tyrosine phosphatases versus inositol phosphatases varies by cell type.
- Understanding these inhibitory mechanisms is key to modulating immune responses.